Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus-Infected Patients.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
01 09 2019
Historique:
pubmed: 21 5 2019
medline: 15 4 2020
entrez: 21 5 2019
Statut: ppublish

Résumé

The presentation of cognitive impairments in HIV-infected individuals has transformed since the introduction of antiretroviral therapies. Although the overall prevalence of cognitive impairments has not changed considerably, frank dementia is now infrequent, and milder forms of cognitive impairments predominate. Mechanistic insights to the underlying causes of these residual cognitive impairments have been elusive, in part due to the heterogenous etiology of cognitive dysfunction in this population. Here, we sought to categorize longitudinal change in HIV-infected patients based on the performance in specific cognitive domains. This study consisted of 193 participants from the CHARTER cohort with detailed demographic, clinical, and neuropsychological testing data obtained from 2 study visits interspersed by ∼6 months. Cognitive testing assessed executive function, learning and delayed recall, working memory, verbal fluency, speed of information processing, and motor skills. Change scores were calculated for each domain between the 2 study visits. Dimension reduction and clustering was accomplished by principal component analysis of change scores and k-means clustering to identify cognitive domains that group together and groups of subjects with similar patterns of change. We identified 4 distinct cognitive change phenotypes that included declines in: (1) verbal fluency, (2) executive function (3) learning and recall, and (4) motor function, with approximately equal numbers of participants in each phenotype. Each of the 4 cognitive change phenotypes identify deficits that imply perturbations in specific neural networks. Future studies will need to validate if cognitive change phenotypes are associated with alterations in associated neural pathways.

Identifiants

pubmed: 31107302
doi: 10.1097/QAI.0000000000002093
pmc: PMC6692206
mid: NIHMS1527804
doi:

Substances chimiques

Antirheumatic Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-70

Subventions

Organisme : NIA NIH HHS
ID : R01 AG057420
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH075673
Pays : United States
Organisme : NIMH NIH HHS
ID : HHSN271201000036C
Pays : United States
Organisme : NIMH NIH HHS
ID : N01MH22005
Pays : United States
Organisme : NIMH NIH HHS
ID : HHSN271201000030C
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110246
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH096636
Pays : United States
Organisme : NIMH NIH HHS
ID : P01 MH105280
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107345
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH080661
Pays : United States

Références

Cognition. 1999 Jan 1;69(3):313-35
pubmed: 10193050
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
J Clin Exp Neuropsychol. 2005 Aug;27(6):665-82
pubmed: 16019643
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
J Clin Exp Neuropsychol. 2010 Jul;32(6):579-89
pubmed: 19890760
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):371-9
pubmed: 21646912
J Clin Exp Neuropsychol. 2012;34(5):476-88
pubmed: 22292479
J Pharmacol Exp Ther. 2012 Dec;343(3):696-703
pubmed: 22984227
J Neurovirol. 2013 Feb;19(1):65-74
pubmed: 23250704
AIDS Behav. 2013 Oct;17(8):2808-15
pubmed: 23299876
PLoS One. 2013;8(3):e58351
pubmed: 23472184
J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):609-16
pubmed: 23722610
Psychiatry Res. 2014 Jan 30;215(1):208-16
pubmed: 24290100
J Clin Exp Neuropsychol. 2014;36(4):356-67
pubmed: 24645772
J Neurovirol. 2014 Aug;20(4):352-61
pubmed: 24760360
J Neurovirol. 2014 Aug;20(4):380-7
pubmed: 24927825
J Neurosci Nurs. 2014 Oct;46(5):292-305
pubmed: 25099061
J Neurovirol. 2015 Aug;21(4):422-32
pubmed: 25791344
Clin Neuropsychol. 2015;29(5):656-77
pubmed: 26367342
J Neurovirol. 2016 Apr;22(2):170-8
pubmed: 26407716
Neurobiol Dis. 2016 Aug;92(Pt B):166-74
pubmed: 26408051
BMC Res Notes. 2015 Sep 30;8:515
pubmed: 26423806
Neurobiol Dis. 2016 Aug;92(Pt B):175-82
pubmed: 26484382
AIDS Care. 2016;28(4):436-40
pubmed: 26573559
AIDS Care. 2016;28(5):628-32
pubmed: 26694807
J Subst Use. 2015;20(6):407-416
pubmed: 26752974
J Neuroimaging. 2016 Jul;26(4):450-7
pubmed: 26780881
Cogn Behav Neurol. 2016 Mar;29(1):1-10
pubmed: 27008244
Neurology. 2016 Jul 12;87(2):148-54
pubmed: 27287217
Alcohol Clin Exp Res. 2016 Nov;40(11):2435-2444
pubmed: 27658235
Curr HIV/AIDS Rep. 2016 Dec;13(6):399-411
pubmed: 27730446
Alcohol Clin Exp Res. 2016 Dec;40(12):2656-2666
pubmed: 27759882
J Infect Dis. 2017 Jan 1;215(1):114-121
pubmed: 27789726
J Neurosci Res. 2017 Jan 2;95(1-2):126-135
pubmed: 27870412
J Neurovirol. 2017 Jun;23(3):422-429
pubmed: 28101804
Eur Radiol. 2017 Nov;27(11):4721-4729
pubmed: 28409354
J Neuroimmune Pharmacol. 2017 Dec;12(4):661-669
pubmed: 28470583
Front Hum Neurosci. 2017 Apr 28;11:212
pubmed: 28503143
AJNR Am J Neuroradiol. 2017 Aug;38(8):1623-1629
pubmed: 28596187
J Clin Exp Neuropsychol. 2018 May;40(4):357-376
pubmed: 28689493
Lancet HIV. 2017 Sep;4(9):e411-e422
pubmed: 28716545
BMC Musculoskelet Disord. 2017 Aug 1;18(1):325
pubmed: 28764704
Appl Neuropsychol Adult. 2019 Jan-Feb;26(1):17-27
pubmed: 28850256
J Int Neuropsychol Soc. 2018 Feb;24(2):163-175
pubmed: 28874213
Neuroradiology. 2017 Nov;59(11):1133-1142
pubmed: 28889255
Neurology. 2017 Oct 10;89(15):1594-1603
pubmed: 28904086
Curr HIV/AIDS Rep. 2017 Oct;14(5):184-199
pubmed: 28933001
AIDS Care. 2018 May;30(5):623-633
pubmed: 29411628
Handb Clin Neurol. 2018;152:21-40
pubmed: 29604978
PLoS One. 2018 Apr 2;13(4):e0195217
pubmed: 29608615
AIDS. 2018 Aug 24;32(13):1849-1860
pubmed: 29746300
AIDS. 2018 Jul 31;32(12):1679-1688
pubmed: 29762177
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):101-107
pubmed: 29847476
Neurology. 2018 Jul 10;91(2):e162-e170
pubmed: 29875216
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):375-380
pubmed: 29957675
Acta Neurol Scand. 1993 Aug;88(2):112-8
pubmed: 8213054
Assessment. 1998 Dec;5(4):375-87
pubmed: 9835661

Auteurs

Raha M Dastgheyb (RM)

Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.

Ned Sacktor (N)

Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.

Donald Franklin (D)

HIV Neurobehavioral Research Program, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA.

Scott Letendre (S)

HIV Neurobehavioral Research Program, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA.

Thomas Marcotte (T)

HIV Neurobehavioral Research Program, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA.

Robert Heaton (R)

HIV Neurobehavioral Research Program, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA.

Igor Grant (I)

HIV Neurobehavioral Research Program, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA.

Justin C McArthur (JC)

Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.

Leah H Rubin (LH)

Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.

Norman J Haughey (NJ)

Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH